HKMPF (Hikma Pharmaceuticals) Total Long-Term Assets: $3,028 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKMPF Hikma Pharmaceuticals PLC HKMPF
82 GF Score
Price $20.37
GF Value $27.43
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Total Long-Term Assets?

Hikma Pharmaceuticals HKMPF 82 Total Long-Term Assets is $3,028 Mil as of Dec. 2025. GuruFocus rates HKMPF with a GF Score™ of 82/100 and a GF Value™ of $27.43 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Hikma Pharmaceuticals's Total Long-Term Assets for the quarter that ended in Dec. 2025 was $3,028 Mil.

Hikma Pharmaceuticals Total Long-Term Assets Related Terms

Hikma Pharmaceuticals Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Hikma Pharmaceuticals's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hikma Pharmaceuticals Total Long-Term Assets Chart

Hikma Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,278.00 2,472.00 2,580.00 2,870.00 3,028.00

Hikma Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,580.00 2,562.00 2,870.00 2,997.00 3,028.00
HKMPF
82GF Score
Hikma Pharmaceuticals PLC HKMPF
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikma Pharmaceuticals Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $3,028 Mil mean?
Hikma Pharmaceuticals (HKMPF) has a Total Long-Term Assets of $3,028 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Hikma Pharmaceuticals and its competitors.
Is Hikma Pharmaceuticals' Total Long-Term Assets too high?
Hikma Pharmaceuticals' current Total Long-Term Assets is $3,028 Mil. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Total Long-Term Assets compare to ZTS and UTHR?
Hikma Pharmaceuticals' Total Long-Term Assets of $3,028 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Hikma Pharmaceuticals and its competitors. Hikma Pharmaceuticals's current Total Long-Term Assets is $3,028 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $27.43, compared to a current price of $20.37 — trading 25.7% below its estimated fair value. The current Total Long-Term Assets is $3,028 Mil. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current Total Long-Term Assets is $3,028 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of $20.37 is trading 25.7% below its estimated GF Value™ of $27.43. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for HKMPF:

  • Total Long-Term Assets: $3,028 Mil
  • GF Value™: $27.43 vs. price of $20.37 (25.7% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score

Get the complete analysis for HKMPF

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.37
Price
$27.43
GF Value